Now Available: Multiple Myeloma Luciferase Cell Lines

Imanis Life Sciences

Menu

B16F10-mNIS-Puro

Species Mouse
Cell Type Melanoma
Transgene Mouse sodium iodide symporter (mNIS)
Selection Gene Puromycin resistance (Puro)
  • Description

    B16F10-mNIS-Puro is a polyclonal population of the murine melanoma cell line B16F10 (ATCC® CRL-6475). To achieve stable reporter expression in the polyclonal population, parental B16F10 cells were transduced with LV-mNIS-PGK-Puro (LV022) and selected using puromycin. LV-mNIS-PGK-Puro encodes the mouse sodium iodide symporter (mNIS) cDNA under the spleen focus-forming virus (SFFV) promoter and the puromycin resistance gene (Puro) under the phosphoglycerate kinase (PGK) promoter.

    *The ATCC trademark and trade name and any and all ATCC catalog numbers are trademarks of the American Type Culture Collection.

    This cell line has been tested for mycoplasma contamination and is certified mycoplasma free.

    The parental B16F10 cell line has been authenticated and certified free of interspecies cross contamination by short tandem repeat (STR) profiling with 9 STR loci.

    Replication Competent Lentivirus (RCL) Test (including a test report) is available for this cell line at an added cost.  Contact us to learn more.

  • Characterization

    Morphology


    B16F10-mNIS-Puro MorphologyLow and high density cell morphology (200x)

    NIS Expression


    B16F10-mNIS-Puro NIS ExpressionCells were incubated with I-125 for one hour in the presence or absence of KClO4, an inhibitor of iodine uptake. Radioiodine concentrated within the cells was measured with a gamma counter.

  • Growth Conditions

    Complete Growth Medium: DMEM supplemented with 10% FBS, 1X Penicillin/Streptomycin, and 1 µg/mL puromycin.

    The addition of puromycin to the complete growth medium maintains high reporter expression over continued passage of the cells. It is highly recommended, especially if the cells undergo multiple passages prior to being used for studies.

    These cells should be grown in the indicated medium and passaged when they reach confluency. For routine passaging, cells are recommended to be split at a 1:10 ratio every 3-4 days.

    B16F10 cells produce melanin; accumulation of melanin turns the cells dark brown or black and prolonged melanin secretion turns cell culture medium black. Melanin is toxic and B16F10 cells will die in the presence of excess melanin. Culture medium should be changed as soon as it becomes black, even if the cells are not confluent. Typically, media changes between passages are not required. Different lots of FBS have been observed to affect the rate of melanin production by B16F10 cells.

    B16F10 cells trypsinize relatively quickly. Excess trypsinization can damage the cells and care should be taken to quickly neutralize the trypsin upon cell detachment.

  • Usage Information

    These cells are suitable for in vitro and in vivo experimentation. B16F10 cells form tumors and pulomary metastases post implantation into syngenic C57BL/6 mice.The NIS transgene facilitates high resolution, 3D SPECT/PET imaging of implanted cells. NIS is not immunogenic and is therefore suitable for longitudinal imaging studies in a syngenic model.

    The cells can be amplified in vitro and used to generate additional frozen stocks. Cryopreservation of low passage stocks is recommended. Frozen stocks should be preserved in a designated cryopreservation medium.

    These cells were generated via lentiviral vector transduction. The lentiviral vector used for transduction was a self-inactivating (SIN) vector in which the viral enhancer and promoter have been deleted. Transcription inactivation of the LTR in the SIN provirus increases biosafety by preventing mobilization by replication competent viruses and enables regulated expression of the genes from the internal promoters without cis-acting effects of the LTR2. Nevertheless, all work with these cells should be performed under biosafety-level 2 (BSL2) conditions by trained personnel. Institutional requirements may permit handling of these cells under BSL1 conditions if certain criteria are met.

    References:
    1Fidler. Cancer Res. 1975. 35:218-224.
    2Miyoshi et al. J Virol 1998. 72:8150-8157.

  • Datasheet/COA

Learn More